December 2, 2017 - By Henry Gaston
Miller Howard Investments Inc decreased Abbott Labs Com (ABT) stake by 3.38% reported in 2017Q2 SEC filing. Miller Howard Investments Inc sold 51,695 shares as Abbott Labs Com (ABT)’s stock declined 3.42%. The Miller Howard Investments Inc holds 1.48 million shares with $71.84 million value, down from 1.53 million last quarter. Abbott Labs Com now has $97.44 billion valuation. The stock decreased 0.69% or $0.39 during the last trading session, reaching $55.98. About 5.32 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since December 2, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.
Among 12 analysts covering Carnival PLC (LON:CCL), 5 have Buy rating, 1 Sell and 6 Hold. Therefore 42% are positive. Carnival PLC had 62 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Carnival plc (LON:CCL) earned “Hold” rating by Numis Securities on Wednesday, December 21. The firm has “Outperform” rating by Credit Suisse given on Thursday, March 31. As per Wednesday, September 23, the company rating was maintained by Credit Suisse. Credit Suisse maintained the stock with “Outperform” rating in Tuesday, November 24 report. On Monday, September 21 the stock rating was maintained by Barclays Capital with “Equal Weight”. The company was maintained on Friday, April 1 by Jefferies. The rating was maintained by Barclays Capital with “Equal-Weight” on Thursday, March 30. The stock of Carnival plc (LON:CCL) has “Equal Weight” rating given on Monday, October 3 by Barclays Capital. Credit Suisse maintained Carnival plc (LON:CCL) on Wednesday, July 5 with “Outperform” rating. The firm earned “Equal Weight” rating on Monday, July 17 by Barclays Capital. See Carnival plc (LON:CCL) latest ratings:
11/10/2017 Broker: Berenberg Rating: Hold Old Target: GBX 4300.00 New Target: GBX 5300.00 Maintain
17/07/2017 Broker: Barclays Capital Rating: Equal Weight Old Target: GBX 5300.00 New Target: GBX 5300.00 Maintain
05/07/2017 Broker: Credit Suisse Rating: Outperform Maintain
26/06/2017 Broker: HSBC Rating: Neutral Old Target: GBX 5200.00 New Target: GBX 5600.00 Maintain
09/06/2017 Broker: Barclays Capital Rating: Equal Weight Old Target: GBX 5020.00 New Target: GBX 5020.00 Maintain
Investors sentiment decreased to 0.88 in 2017 Q2. Its down 0.75, from 1.63 in 2017Q1. It turned negative, as 69 investors sold ABT shares while 545 reduced holdings. 102 funds opened positions while 441 raised stakes. 1.22 billion shares or 0.83% more from 1.21 billion shares in 2017Q1 were reported. Davidson Garrard holds 22,173 shares. 23,261 were accumulated by Cim Investment Mangement. Piedmont Investment Advsr Limited Liability stated it has 376,514 shares or 0.41% of all its holdings. Bahl And Gaynor invested in 1.74% or 3.70M shares. Pnc Financial Services Group owns 0.38% invested in Abbott Laboratories (NYSE:ABT) for 7.27 million shares. Andra Ap holds 0.35% or 290,900 shares. Nbt Bancorp N A New York owns 119,076 shares for 0.94% of their portfolio. Northstar Gru invested in 0.29% or 9,502 shares. Ci Invests Incorporated has invested 0% in Abbott Laboratories (NYSE:ABT). Covington Cap Mngmt owns 0.76% invested in Abbott Laboratories (NYSE:ABT) for 194,358 shares. Utd Commercial Bank Va owns 95,769 shares or 4.53% of their US portfolio. Dearborn Prns Limited Liability Company owns 62,212 shares for 0.22% of their portfolio. Sigma Planning Corporation has 0.14% invested in Abbott Laboratories (NYSE:ABT) for 30,104 shares. Thomaspartners Inc holds 2.04% or 4.89 million shares in its portfolio. First Foundation Advisors invested 0.03% in Abbott Laboratories (NYSE:ABT).
Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on January, 24. They expect $0.73 earnings per share, up 12.31% or $0.08 from last year’s $0.65 per share. ABT’s profit will be $1.27 billion for 19.17 P/E if the $0.73 EPS becomes a reality. After $0.66 actual earnings per share reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 10.61% EPS growth.
Among 24 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. Abbott Laboratories had 87 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Friday, February 5 by Argus Research. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Jefferies on Tuesday, October 10. The firm has “Buy” rating by Jefferies given on Monday, December 7. Stifel Nicolaus maintained Abbott Laboratories (NYSE:ABT) on Friday, September 22 with “Buy” rating. The firm earned “Buy” rating on Friday, July 21 by Argus Research. The firm earned “Buy” rating on Tuesday, June 14 by Jefferies. The rating was maintained by BMO Capital Markets with “Market Perform” on Thursday, October 19. As per Friday, June 16, the company rating was maintained by Jefferies. As per Saturday, August 29, the company rating was maintained by Deutsche Bank. The stock of Abbott Laboratories (NYSE:ABT) earned “Outperform” rating by RBC Capital Markets on Friday, October 9.
Miller Howard Investments Inc increased Bank Montreal Que Com (NYSE:BMO) stake by 143,813 shares to 890,626 valued at $65.41M in 2017Q2. It also upped Telephone & Data Sys Inc Com N (NYSE:TDS) stake by 99,061 shares and now owns 215,636 shares. Bce Inc Com New (NYSE:BCE) was raised too.
Since June 15, 2017, it had 0 buys, and 1 insider sale for $26,482 activity. Watkin Jared had sold 552 shares worth $26,482 on Thursday, June 15.
Carnival plc operates as a leisure travel and cruise firm in North America, Europe, Australia, and Asia. The company has market cap of 34.28 billion GBP. It offers cruises under the Carnival Cruise Line, Princess Cruises, Holland America Line, and Seabourn brands in North America; and Costa, AIDA, P&O Cruises , Cunard, and P&O Cruises (Australia) brands in Europe, Australia, and Asia. It has a 12.96 P/E ratio. The firm operates approximately 100 cruise ships.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.